Recent Drugs Hailed as a 'Pivotal Moment' in Addressing Drug-Resistant Gonorrhoea

The initial novel therapies for gonorrhoea in decades are being hailed as a "huge turning point" in the fight against drug-resistant strains of the infection, according to health experts.

A Worldwide Health Concern

Gonorrhoea infections are increasing around the world, with figures suggesting over 82 million new cases each year. Particularly high rates are observed in Africa and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary step in the face of rising global incidence, increasing antimicrobial resistance and the very limited available drugs at this time.”

Public health authorities are particularly alarmed about the rise in treatment-resistant strains. The WHO has classified it as a "priority pathogen". A tracking program revealed that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Receive Approval

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US Food and Drug Administration in December for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts believe that specific application of this new drug will help slow the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This medication, which is also used to treat urinary tract infections, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment emerged from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to see it through.

“This milestone represents a significant shift in the treatment of superbug gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Testing Results and Worldwide Availability

Based on findings detailed in a prominent scientific publication, zoliflodacin cured more than 90% of genital gonorrhoea infections. This establishes an comparable level with the existing first-line therapy, which uses a dual-drug approach. The study involved hundreds of volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the rights to license and sell the drug in numerous developing nations.

Clinicians treating patients have expressed hope. The availability of a easy-to-administer therapy of this kind is hailed as a "critical tool" for gonorrhoea control. This is deemed vital to lessen the impact of the illness for individuals and to stop the proliferation of untreatable gonorrhoea worldwide.